Nykode Therapeutics ASA
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
NYKD | OL
Overview
Corporate Details
- ISIN(s):
- NO0010714785
- LEI:
- 254900UKQHWYZJD22017
- Country:
- Norway
- Address:
- Gaustadalleen 21, 0349 Oslo
- Website:
- https://nykode.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines. The company's core is its innovative, modular technology platform centered on the proprietary Vaccibody™ molecule. This platform is engineered to deliver antigens with tailored hyper-targeting to Antigen Presenting Cells, inducing rapid, robust, and long-lasting immune responses. Nykode's approach demonstrates a positive safety profile and has the potential to treat and prevent a wide range of diseases, with a significant focus on cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-10 17:44 |
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment Options 2…
|
Norwegian | 181.6 KB | ||
| 2025-10-10 17:44 |
Director's Dealing
Nykode Therapeutics – Grant of Share Options
|
Norwegian | 775 bytes | ||
| 2025-10-10 14:00 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
Norwegian | 199.2 KB | ||
| 2025-10-10 14:00 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
Norwegian | 778 bytes | ||
| 2025-10-10 12:36 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
Norwegian | 189.4 KB | ||
| 2025-10-10 12:36 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
Norwegian | 708 bytes | ||
| 2025-10-09 20:27 |
Report Publication Announcement
Financial calendar
|
English | 473 bytes | ||
| 2025-08-27 07:01 |
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
|
English | 176.0 KB | ||
| 2025-08-27 07:01 |
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
|
English | 12.9 KB | ||
| 2025-08-27 07:00 |
Interim Report
Nykode Therapeutics - Quarterly report Q2 2025 - Attachment: 250827 Nykode Quar…
|
English | 11.4 MB | ||
| 2025-08-27 07:00 |
Report Publication Announcement
Nykode Therapeutics - Quarterly report Q2 2025
|
English | 3.0 KB | ||
| 2025-08-20 08:00 |
Report Publication Announcement
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and …
|
English | 125.6 KB | ||
| 2025-08-20 08:00 |
Report Publication Announcement
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and …
|
English | 3.3 KB | ||
| 2025-07-09 18:15 |
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment 250709.pdf
|
English | 213.3 KB | ||
| 2025-07-09 18:15 |
Remuneration Information
Nykode Therapeutics – Grant of Share Options
|
English | 1.1 KB |
Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
